|
|
Upfront Briefing
Ultragenyx waited for the closing bell before telling everyone Angelman didn't work. Aspire missed on cognition and on all five domains of the responder index, and the same release announced significant expense reductions — the corporate equivalent of failing the exam and immediately cancelling your subscriptions. Elsewhere the FDA published an editorial promising harder looks at overseas trial sites, which is awkward timing for anyone whose pipeline arrived by container ship from Shanghai. Novartis signed up for Alteogen's needle at a $3.22B ceiling. Halozyme may want to sit down.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,666.6 |
0.5% |
11.8% |
| Nasdaq 100 |
29,143.3 |
0.2% |
15.6% |
| Russell 2000 |
2,953.2 |
1.1% |
17.7% |
| Healthcare (XLV) |
172.9 |
0.8% |
11.2% |
| Biotech (XBI) |
165.4 |
1.2% |
36.1% |
| Nasdaq Biotech (NBI) |
7,287.4 |
1.3% |
27.7% |
| Clinical Trials (BBC) |
53.8 |
1.6% |
42.9% |
|
- Biotech led the tape, with XBI up 1.2% and NBI up 1.3% against XLV's 0.8% — roughly a 50bp gap to large-cap healthcare — on a session whose tradeable biopharma news was Teva's celiac Phase 2a win and the Novartis–Alteogen licence, both pre-close.
- Equities carried the rebound while the bond market sat it out: the 10-year closed at 4.768%, roughly a basis point lower after touching 4.818% intraday — its highest since November 2023 — with TLT up just 0.1% and VIX at 15.16. ADP's August private payrolls came in at 38,000 against a 47,000 consensus, ahead of Friday's nonfarm print.
- Market data: U.S. cash close Wednesday, 2 September 2026.
The Big 3
|
1
|
Ultragenyx Angelman therapy fails Phase 3 trial
|
- Ultragenyx's apazunersen (GTX-102) missed both the Bayley-4 cognition primary and the MDRI key secondary in the 129-patient Phase 3 Aspire study, with safety consistent with Phase 1/2.
- Why it matters: Aspire enrolled 129 patients with full maternal UBE3A deletion and missed the Bayley-4 cognition primary and the MDRI secondary, with no separation on any of the five MDRI domains. Evercore called it a clean fail Thursday, cutting to In Line and taking its target to $16 from $34. RARE closed the regular session at $26.53 and traded down 43.7% after the bell, erasing about $1.14B of market value. What is left is a commercial story: GENGLYCOS launched, UX111 pending, $436M of cash against a $489M trailing burn, and significant expense reductions announced in the same release as the miss. The 2027 profitability target now rests on cost, not pipeline.
- Source: STAT
- More: BioPharma Dive; GlobeNewswire
|
|
2
|
FDA signals tighter scrutiny of foreign trial data
|
- Leaders of key FDA divisions published an editorial Wednesday vowing to expand oversight of foreign clinical trial sites, and said the agency has increased BIMO inspector headcount at its China office.
- Why it matters: The editorial is the first formal move toward holding overseas sites to US good clinical practice standards, and the agency says it has already added BIMO inspectors at its China office. The stated concern is early feasibility and Phase 1 work in regions where the FDA doubts consent was freely given, which is precisely where the fast, cheap China data underwriting the current BD&L wave gets generated. Sponsors running ex-US packages should budget for longer pre-submission engagement and more inspection spend. This stacks on top of House Appropriations language that would bar China-generated IND data outright, so the regulatory discount on China-sourced assets widens rather than clears.
- Source: Endpoints
- More: BioSpace
|
| 3 | Novartis licenses Alteogen's ALT-B4 in deal capped at $3.22B |
- Alteogen granted Novartis multiple options to develop subcutaneous formulations of several products using ALT-B4, worth up to $3.223B in option-exercise fees, milestones and royalties. No upfront was disclosed.
- Why it matters: No upfront was disclosed — Alteogen took $20M up front from Biogen and from GSK earlier this year on deals capped at $549M and $265M, so the near-term cash here is small and the timing control sits with Novartis. The $3.22B is option-exercise fees, milestones and royalties across several unnamed Novartis biologics. The tradeable read-through is Halozyme, which has owned subcutaneous conversion via ENHANZE and now faces a rival platform carrying Merck, AstraZeneca, Biogen, GSK and Novartis on its reference list. This is Alteogen's fourth licence of 2026, lifting its cumulative ceiling to $4.45B. SC conversion is now defensive table stakes for any IV biologic facing an SC competitor.
- Source: Fierce Biotech
- More: Contract Pharma; Seeking Alpha
|
Everything Else that broke
- CBER scrutiny deepened after a report that a senior official overruled reviewers on Replimune's melanoma drug Tudriqev. — STAT
- uniQure moved toward an FDA filing for its Huntington's gene therapy after a bruising stretch with regulators. — BioPharma Dive
- Teva's anti-IL-15 antibody TEV-408 met its primary endpoint in a 50-patient Phase 2a gluten-challenge study, cutting biopsy-measured intestinal damage versus placebo after a single subcutaneous dose; there are no approved celiac therapies. — Fierce Biotech
- ARPA-H committed $125M to personalized RNA drug production, keeping government backing behind custom manufacturing infrastructure. — Fierce Pharma
- Novartis flagged about 130 Switzerland job cuts as it reworks biologics development and production in Basel. — Fierce Pharma
- The UK halted Tavneos sales, with the MHRA said to be following the EMA's lead. — MHRA
- TScan Therapeutics will cut 75% of its workforce and pause its hematological and autoimmune programs to concentrate on solid tumors. — Fierce Biotech
- The SEC and FDA signed a three-year information-sharing agreement, framed as a signal to the market on insider trading around regulatory decisions. — Fierce Biotech
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- HUTCHMED licensed ex-Greater China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted conjugate, to a GSK subsidiary for $110M up front, up to $1.185B in milestones and tiered royalties. — GlobeNewswire
- Fortrea agreed to buy Worldwide Clinical Trials' early-phase division for $45M, expanding its CRO footprint. — Fierce Biotech
- Alteogen granted Novartis option and licence rights to ALT-B4 for subcutaneous conversion of multiple products, worth up to $3.223B in option fees, milestones and royalties; no upfront disclosed. — Fierce Biotech
VC / Private Financings
- Typewriter Therapeutics emerged from stealth with a $56M Series A led by AN Venture Partners and RA Capital Management, joined by ANRI, Gemseki and SBI US Gateway Fund, to pursue in vivo CAR-T. — PR Newswire
- SciBase launched a rights issue of approximately SEK 58M. — PR Newswire
IPOs / Follow-Ons
- Rainier Acquisition's underwriter exercised its over-allotment in full, bringing total IPO gross proceeds to $86.25M. — GlobeNewswire
- Futura Medical launched a formal sale process and broader M&A review alongside a £1.6M fundraise, putting strategic alternatives officially in play. — Investegate
Academic Corner - Among 16 patients with refractory neurologic autoimmune disorders, lentiviral in vivo CD19 CAR-T showed manageable side effects, complete B-cell depletion, and preliminary clinical improvement. — NEJM
- A NEJM review on pulmonary nodules focused on imaging follow-up, cancer risk, and avoiding unnecessary procedures. — NEJM
|
|
Three deaths, one clean fail, and a needle. See you tomorrow.
— BioBucks Team
|
|
|
